TransCode Therapeutics, Inc. (RNAZ) Stock

TransCode Therapeutics, Inc. is a pioneering ribonucleic acid (RNA) oncology company dedicated to advancing the forefront of drug development and diagnostics for the identification and treatment of metastatic diseases. At its core, TransCode Therapeutics focuses on leveraging RNA-based technologies to innovate therapies that target critical pathways involved in metastasis. The company's lead therapeutic candidate, TTX-MC138, specifically targets microRNA-10b, recognized as a pivotal regulator of metastatic cell viability across a spectrum of cancers including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.

In addition to TTX-MC138, TransCode Therapeutics is actively developing a robust pipeline of innovative RNA-based therapies. This includes TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, and TTX-siLIN28B, an siRNA-based inhibitor targeting the RNA-binding protein LIN28B. Furthermore, the company is advancing TTX-RIGA, an RNA-based agonist designed to activate innate immunity within the tumor microenvironment, TTX-CRISPR a CRISPR/Cas9-based therapy platform aimed at repairing or eliminating cancer-causing genes within tumor cells and TTX-mRNA, an mRNA-based platform for developing cancer vaccines that stimulate cytotoxic immune responses against tumors.

Founded in 2016 and headquartered in Boston, Massachusetts, TransCode Therapeutics is committed to translating cutting-edge RNA research into transformative therapies. With a strong emphasis on precision medicine and innovative therapeutic strategies, the company aims to significantly impact the landscape of cancer treatment, offering new hope to patients confronting metastatic disease worldwide.